

Implementing GS1 Standards in Novartis

Minimizing risk and reinforcing patient safety

Margarida Alves and Michael Ritter 25 October 2012



Agenda




- Objectives
- •Big picture
- Implementing GS1 Standards in Novartis
- Regulatory requirements (EU and US)
- Front end hospital
- Current Status and conclusions
- **U** NOVARTIS


Implementing GS1 Standards in Novartis Objectives

- Register the course of the medicine (not only at the level of the lot, but the unit itself) from production to administration at the hospital (patient, date and time)
- Ensure that the unique identifier on the product is registered in a database
- Enable online status check in case of an adverse event or any investigations by quality
- Support the process of dispensing and tracking in the Hospital (from pharmacy till the surgery room)
- Online verification of batch and shelf life
- Reduce risk of exchanging drugs

Portugal Project Big picture




Product box – label applied on the bottom of the box



Project and the EU Directive on Falsified Medicines


This is the first project in Novartis Pharma that supports the process of dispensing and tracking in the Hospital.

Regulatory timelines: California ePedigree law and EU directive on falsified medicines (FMD)



Verification Concept US & EU

US e-Pedigree law requires significantly higher technical and transactional granularity



EFPIA proposes usage of data matrix for pack verification

Data matrix coding proposal derived from GS1 standards (EAN 128 syntax with Application Identifiers; Data matrix ECC200)

Manufacturer Product Code (GTIN or NTIN) Unique Serial Number (randomized) Expiry Date Batch Number

14 digits up to 20 alpha-numeric characters 6 digits (YYMMDD) up to 20 alpha-numeric characters

+ minimum requirements on quality of randomization

Example:

GTIN:	(01)09876543210982
Batch:	(10)A1C2E3G4I5
Expiry:	(17)140531
S/N:	(21)12345AZRQF1234567890

Specifications provided in EFPIA's "European Pack Coding Guidelines"





Implementing GS1 Standards in Novartis Frontend hospital application access

It is a web based application therefore the access is very simple: <u>www.trace.novartis.com</u>



 Each hospital has access with as many users as necessary.



Implementing GS1 Standards in Novartis Although the technology is complex the system is simple

Upon prescription the pharmacist scans the packs. Serial number, date and time of dispensing are recorded.

					- 0
e Edit View Favorites Tools Help					
Back 🝷 🕥 🖌 😰 🚺 🔎 Search	h 🤺 Favorites 🧭	🛛 🗟 • 🍓 🔜 🔜 🧕	10		
iress 🗃 http://ttint1.eu.novartis.net:8001/sap/bc/v				💽 🕞 Go 🛛 Links 🎽 🛄 Snagit 🗮 📷	1
Programa de Pastre	abilidada da Adr	ninistração intra-vítrea d	le Panihizumah		
i rograma de Rastre	abilitade de Adi	innon açao inn a-vin ea t			
SPITAL DE SANTA MARIA					
Código do produto 📃 🚊	Data da dispensa	Hora da dispensa Data	a do Tratamento Status 📃		
(01)0-560035161-300-0(21)75011221628961	26.10.2010	11:50:17			
(01)0-560035161-300-0(21)75011221629097	26.10.2010	11:50:58 Adicionar códi	go de produto		
(01)0-560035161-300-0(21)75011221629176	26.10.2010	11:51:30	o: * (01)0-560035161-300-0(21)75011221629245		
		Utilizador: *	ALVESMA1		
				Gravar Cancelar	
. de processo encriptado	Data do Tratamento	Olho direito/olho esquerdo			
	Data do Hatamonto				
inner Inneinie fann diele Dahmeine fann diele	0 diningan bl0 da a	Demours sódins de sus ±4-175	unter medite - Buildión - Engling - Ling Off		
impar Imprimir formulário Reimprimir formulário	Adicionar Nº, de process	o Remover código do produto De	volver produto Relatório Finalizar Log Off		
	Adicionar Nº, de process	o Remover código do produto De	volver produto Relatório Finalizar Log Off		
	Adicionar Nº, de proces:	o Remover código do produto De	volver produto Relatório Finalizar Log Off		
Limpar Imprimir formulário Reimprimir formulário 2M Link to EMA, Email	Adicioner Nº, de process	o Remover código do produto De	volver produto Relatório Finalizar Log Off		



Implementing GS1 Standards in Novartis Printing shipping document

The product is then sent from the hospital pharmacy into the surgery room with an internal shipping document containing the serial number, batch number and shelf life.

Formu					
	I 🚔 🎘 🦚 🕷 🖉 🕨 📷 I 🔍 - 🚺 🗄	93% • 🟵 🂾 •	1 In the second	🖹 🖉 - 🛛 🎽	?
- 7 1					
Ges					
Pa					
			Data	2010/10/26	
-					
	FORMULÁRIO DE DISPENSA DE RA	ANIBIZUMAB PARA INJECÇÂ	O INTRAV	ÍTREA	
	Ampolas dispensadas	Prazo de validade	Lote n°.		
ments	(01)0-560035161-300-0(21)75011221628961	2012/01/31	S0014A		
	(01)0-560035161-300-0(21)75011221629097	2012/01/31	S0014A		
	(01)0-560035161-300-0(21)75011221629176	2012/01/31	S0014A		
	(01)0-560035161-300-0(21)75011221629245	2012/01/31	S0014A		
					OK
	Comments Attachments	FORMULÁRIO DE DISPENSA DE RA Ampolas dispensadas (01)0-560035161-300-0(21)75011221628961 (01)0-560035161-300-0(21)75011221629097 (01)0-560035161-300-0(21)75011221629176 (01)0-560035161-300-0(21)75011221629245	FORMULÁRIO DE DISPENSA DE RANIBIZUMAB PARA INJECÇÃ Ampolas dispensadas Prazo de validade (01)0-560035161-300-0(21)75011221628961 2012/01/31 (01)0-560035161-300-0(21)75011221629097 2012/01/31 (01)0-560035161-300-0(21)75011221629176 2012/01/31 (01)0-560035161-300-0(21)75011221629176 2012/01/31 (01)0-560035161-300-0(21)75011221629245 2012/01/31	Control Data Hora Hora FORMULÁRIO DE DISPENSA DE RANIBIZUMAB PARA INJECÇÃO INTRAV Ampolas dispensadas Prazo de validade Lote n°. (01)0-560035161-300-0(21)75011221628961 2012/01/31 \$0014A (01)0-560035161-300-0(21)75011221629097 2012/01/31 \$0014A (01)0-560035161-300-0(21)75011221629176 2012/01/31 \$0014A (01)0-560035161-300-0(21)75011221629245 2012/01/31 \$0014A	Market Data 2010/10/26 Hora 11:52:08 FORMULÁRIO DE DISPENSA DE RANIBIZUMAB PARA INJECÇÃO INTRAVÍTREA Ampolas dispensadas Prazo de validade Lote n°. (01)0-560035161-300-0(21)75011221628961 2012/01/31 S0014A (01)0-560035161-300-0(21)75011221629097 2012/01/31 S0014A (01)0-560035161-300-0(21)75011221629176 2012/01/31 S0014A (01)0-560035161-300-0(21)75011221629245 2012/01/31 S0014A

Implementing GS1 Standards in Novartis Scanning and inserting patient code

After administration the pack is again scanned and the internal patient code is introduced manually or by scanning the patient barcode if available.

Programa de Rastreabilidade de Administraçã	ão intra-vítrea de - Micro	osoft Internet	Explorer provided by N	wartis				_ 🗆 ×
Edit View Favorites Tools Help								2
) Back 🔹 💮 🖂 💌 😰 🏠 🔎 Searc	th 🤺 Favorites 🥝	🔊 - 🎍	🔜 📃 🔯					
dress 🕘 http://ttint1.eu.novartis.net:8001/sap/bc/	webdynpro/sap/zptz_aii_ho	spital?sap-client	=010&sap-language=PT		💌 ラ Go	Links 🎽 🛄 Snagit	E	- (P)
								-
Programa de Rastre	abilidade de Adm	inistração	intra-vítrea de Ra	nibizumab				
OSPITAL DE SANTA MARIA								
	Data da dispensa	Hora da disp	ensa Data do Trat	amento Status				
(01)0-560035161-300-0(21)75011221628961	26.10.2010	11:56:02	26.10.2010	ADMINISTRADA				
(01)0-560035161-300-0(21)75011221629176	26.10.2010	11:52:08	Adicionar Nº. de proce				1	
(01)0-560035161-300-0(21)75011221629245	26.10.2010	11:52:08						
			Código do produto: Nº. de processo: *	(01)0-560035161-300-0(21)75011221628961 22222222				
			Utilizador: *	ALVESMA1				
			Data do Tratamento:	26.10.2010				
				C Esquerdo				
			Olho direito/olho esquerde	c O Direito				
					Gr	avar Cancelar		
							1	
Nº. de processo encriptado	Data do Tratamento	Olho direito/ol	ho esquerdo					
FAA889EEBAD9F42792F02201E4AB09438F65F03	26.10.2010	ESQUERDO						
Limpar Imprimir formulário Reimprimir formulário	Adicionar Nº, de processo	Remover cód		oduto Relatório Finalizar Log Off				
CM Link to EMA Email								
								-
Done							ocal intranet	



Implementing GS1 Standards in Novartis Reports

The patient data remains confidential during the entire process through a complex encryption system.

G Back - S - 💌 😰 🏠 🔎 Se Address 🍯 https://www.trace.novartis.com/sap/bc						💌 🛃 Go 📖	Spacet 📷 💓
Address en https://www.trace.novartis.com/sap/bc	./webdynpro/sap/zptz_aii_r	reports/11P=HP18sap-ci	ienc=010ssap-ianguage=P1			_ _ G0 _ _	onagit 🔚 🖃
Critérios de pesquisa							
Data da leitura óptica: 🗢 🔝 Até							
ta do Tratamento: 🗮 26.10.2010 🔯 Até	é 🛛 🛅 🖻						
umero do lote:							
Nº, de processo:							
Executar							
Resultado							
Visão [Visão standard] Exportação	2.4						Fit
Código eletrônico de prod Exportação para Exce		Hora do registo	Data do Tratamento	Status	Utilizador	Nº, de processo	Olho direito/olh
(01)0-560035161-300-0(21)75011221629698	26.10.2010	11:39:29	26.10.2010	ADMINISTRADA	ALVESMA1	76E3BA58F7E0D72301671E9625230C06EE4F2	. DIREITO
(01)0-560035161-300-0(21)75011221629698	26.10.2010	11:39:34	26.10.2010	CONFIRMADA	ALVESMA1		
(01)0-560035161-300-0(21)75011221628961	26.10.2010	11:56:02	26.10.2010	ADMINISTRADA	ALVESMA1	FFAA889EEBAD9F42792F02201E4AB09438F6	. ESQUERDO
(01)0-560035161-300-0(21)75011221628961	26.10.2010	11:57:02	26.10.2010	ADMINISTRADA	ALVESMA1	96B4F4F53F241F6211130EA35B38F1C215693	. DIREITO
(01)0-560035161-300-0(21)75011221629176	26.10.2010	11:58:07	26.10.2010	ADMINISTRADA	ALVESMA1	FFAA889EEBAD9F42792F02201E4AB09438F6	. DIREITO
(01)0-560035161-300-0(21)75011221629176	26.10.2010	11:59:27	26.10.2010	ADMINISTRADA	ALVESMA1	FFAA889EEBAD9F42792F02201E4AB09438F6	. ESQUERDO

In the hospital reports are available by "Date of scanning", by "Date of treatment", by "Batch number" and by "Patient number"

U NOVARTIS

Implementing GS1 Standards in Novartis Status and conclusion

- Since September 2010 all units of ranibizumab available in Portugal have data matrix code with serial number.
- The pilot in hospitals started in October 2010 in Instituto Oftalmológico Dr. Gama Pinto. During 2011, 4 other public hospitals joined the pilot, 979 treatments have been tracked and traced.
- The pilot project designed and developed in Portugal is under evaluation for adoption in Spain.
- Project very well perceived, with great potential to expand to other products in areas where a more restricted control over medication is needed, such as oncology.



Questions & answers



Thank You!

NOV/24/10/2012





© Novartis Pharma AG, 2012. All rights reserved. Proprietary and Confidential.

"The use and property of this presentation belongs exclusively to Novartis and/or its affiliates Novartis does not make and expressly disclaims: (a) any representation or warranty (express or implied) with respect to the Information show in this presentation, (b) any liability relating the accuracy or completeness of the Information. "